A Study of Stapokibatrt in Children Subjects With Atopic Dermatitis

A Multi-center, Single-arm, Open-label Study to Evaluate the Safety and Efficacy of Stapokibatrt in Children With Atopic Dermatitis

This is a multi-center, single-arm, open-label phase 3 study to evaluate the safety, efficacy, Pharmacokinetics(PK) and immunogenicity of Stapokibatrt in children with Atopic Dermatitis.

Inclusion Criteria:

• Voluntarily participate in the continuing study and sign the written Informed Consent Form(ICF).
• Subjects who must complete the evaluation of Week 18 of the main study.
• Have the ability to communicate well with the researcher and comply with the follow-up visits of the protocol.

Exclusion Criteria:

• Planned major surgical procedure during the patient's participation in this study.
• Any other circumstances in which the researcher deems not suitable to participate in this study.